Press Release Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of…Reset PharmaJanuary 5, 2023
Press Release Reset Pharmaceuticals Announces Appointment of Neuroscience Industry Leader Lisa Deschamps to the Board of Directors Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development and…Reset PharmaNovember 2, 2022
Press Release Stephen Ross, M.D., Chair of Reset Pharma’s Scientific Advisory Board to Deliver Keynote Presentation at The End in Mind Virtual Conference Reset Pharmaceuticals, Inc. (Reset Pharma) announced today that Stephen Ross, M.D., Chair of Reset Pharma’s…Reset PharmaOctober 14, 2021
End-Of-Life Care Is The New Frontier In Psychedelic-Assisted Therapy [via Forbes] https://www.forbes.com/sites/benjaminadams/2021/09/24/the-end-in-mind-conference-answers-questions-about-psychedelics-for-end-of-life-patients/
Press Release Reset Pharmaceuticals Enters into Exclusive Worldwide License Agreement with NYU Langone Health for Intellectual Property and Data on Psilocybin and Related Psychedelics for the Treatment of Mental Illness in Patients with Life-Threatening Diseases, Including Cancer Transaction accelerates Reset Pharmaceuticals’ lead psilocybin program, targeting severe demoralization, as well as anxiety, and…Reset PharmaJuly 7, 2021